Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

Evaluation committee members

This topic was considered as a streamlined evaluation by the chair, vice chair and a subset of committee A.

Committee members are asked to declare any interests in the technology being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

Chair

James Fotheringham
Vice Chair, technology appraisal committee A

NICE project team

Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the evaluation), a technical adviser, a project manager, and an associate director or principal technical adviser.

Anna Willis
Technical Lead

Albany Chandler
Technical Adviser

Jennifer Upton
Project Manager

Ian Watson
Associate Director

ISBN: 978-1-4731-9490-8